Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.

Metzger-Filho O, de Azambuja E, Bradbury I, Saini KS, Bines J, Simon SD, Dooren VV, Aktan G, Pritchard KI, Wolff AC, Smith I, Jackisch C, Lang I, Untch M, Boyle F, Xu B, Baselga J, Perez EA, Piccart-Gebhart M.

Oncologist. 2013;18(2):134-40. doi: 10.1634/theoncologist.2012-0342.

2.

Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.

Fleeman N, Bagust A, Boland A, Dickson R, Dundar Y, Moonan M, Oyee J, Blundell M, Davis H, Armstrong A, Thorp N.

Health Technol Assess. 2011;15(42):1-93, iii-iv. doi: 10.3310/hta15420. Review.

3.

Trastuzumab-containing regimens for metastatic breast cancer.

Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, D'Amico R.

Cochrane Database Syst Rev. 2014 Jun 12;(6):CD006242. doi: 10.1002/14651858.CD006242.pub2. Review.

PMID:
24919460
4.

Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.

Vici P, Viola G, Botti C, Rossi S, Vitucci C, Corsetti S, Di Lauro L, Sergi D, Foggi P, Perri P, Tirelli C, Mottolese M, Fattoruso SI, Lopez M.

Clin Ter. 2008 Nov-Dec;159(6):449-52. Review.

PMID:
19169607
5.

Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.

Cameron DA, Stein S.

Nat Clin Pract Oncol. 2008 Sep;5(9):512-20. doi: 10.1038/ncponc1156. Review.

PMID:
18594499
6.

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.

Baselga J, Perez EA, Pienkowski T, Bell R.

Oncologist. 2006;11 Suppl 1:4-12. Review.

7.

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M.

Breast. 2013 Aug;22 Suppl 2:S152-5. doi: 10.1016/j.breast.2013.07.029. Review.

PMID:
24074778
8.

Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.

Monnier A.

Expert Rev Anticancer Ther. 2006 Oct;6(10):1355-9. Review.

PMID:
17069521
9.

A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.

Larsen PB, K├╝mler I, Nielsen DL.

Cancer Treat Rev. 2013 Nov;39(7):720-7. doi: 10.1016/j.ctrv.2013.01.006. Review.

PMID:
23481218
10.

Clinical trials of Herceptin(trastuzumab).

Baselga J.

Eur J Cancer. 2001 Jan;37 Suppl 1:S18-24. Review.

PMID:
11167087
11.

Primary systemic therapy in HER2-amplified breast cancer: a clinical review.

Khasraw M, Bell R.

Expert Rev Anticancer Ther. 2012 Aug;12(8):1005-13. doi: 10.1586/era.12.62. Review.

PMID:
23030220
12.

Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.

Miles D, Zielinski C, Martin M, Vrdoljak E, Robert N.

Eur J Cancer. 2012 Mar;48(4):482-91. doi: 10.1016/j.ejca.2011.12.007. Review.

PMID:
22257791
13.

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

Zardavas D, Fouad TM, Piccart M.

Breast. 2015 Nov;24 Suppl 2:S143-8. doi: 10.1016/j.breast.2015.07.034. Review.

PMID:
26255196
14.

HER2-positive breast cancer: update on Breast Cancer International Research Group trials.

Nabholtz JM, Reese DM, Lindsay MA, Riva A.

Clin Breast Cancer. 2002 Oct;3 Suppl 2:S75-9. Review.

PMID:
12435291
15.
16.

From the trastuzumab era to new target therapies: beyond revolution.

Barni S, Petrelli F, Cabiddu M, Cazzaniga ME, Cremonesi M.

Ann Oncol. 2007 Jun;18 Suppl 6:vi1-4. Review. No abstract available.

PMID:
17591799
17.

External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer.

Booth CM, Dranitsaris G, Gainford MC, Berry S, Fralick M, Fralick J, Sue J, Clemons M.

BMC Cancer. 2007 Jun 28;7:110. Review.

18.

[The new generation of breast cancer clinical trials: the right drug for the right target].

de Azambuja E, Cardoso F, Meirsman L, Straehle C, Dolci S, Vantongelen K, Piccart-Gebhart M.

Bull Cancer. 2008 Mar;95(3):352-7. doi: 10.1684/bdc.2008.0587. Review. French.

19.

Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.

Del Mastro L, Lambertini M, Bighin C, Levaggi A, D'Alonzo A, Giraudi S, Pronzato P.

Expert Rev Anticancer Ther. 2012 Nov;12(11):1391-405. doi: 10.1586/era.12.107. Review.

PMID:
23072512
20.

Lapatinib in metastatic breast cancer.

Frenel JS, Bourbouloux E, Berton-Rigaud D, Sadot-Lebouvier S, Zanetti A, Campone M.

Womens Health (Lond). 2009 Nov;5(6):603-12. doi: 10.2217/whe.09.54. Review.

PMID:
19863462
Items per page

Supplemental Content

Support Center